Shots:

• Jnana will receive $50M up front & is eligible to receive near-term milestones & additional future milestones of ~$2B along with royalties
• Under the terms of the agreement, Jnana will be responsible to conduct discovery & preclinical activities against multiple cancer, immune-mediated & neurological disease targets. Roche will lead the development and commercialization of any resulting products
• The collaboration allows Jnana to discover novel small molecule drugs directed to targets across a diverse range of target classes in cancer, immune-mediated and neurological diseases by using its RAPID chemoproteomics platform. The collaboration also includes multiple targets to address the unmet medical needs of patients

Ref: Jnana Therapeutics | Image: Roche